Drug Profile


Alternative Names: ARRx; AZD 5312; IONIS AR 2.5Rx; ISIS ARRX; ISIS AZ1Rx; ISIS-560131; ISIS-ARRx

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Solid tumours

Most Recent Events

  • 03 Oct 2017 University of Michigan Cancer Center plans the phase II ARRO-CITO trial for castration-resistant Prostate cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV, Infusion) (NCT03300505)
  • 15 Nov 2016 Adverse events, pharmacokinetic and pharmacodynamic data from a phase I/II trial in advanced solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 Jun 2016 Phase-II clinical trials in Prostate cancer (Late-stage disease) in United Kingdom and USA (IV) (Ionis Pharmaceuticals pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top